The Mucoadhesive Nanoparticle-Based Delivery System in the Development of Mucosal Vaccines
Kai Zhao,Yinzhuo Xie,Xuezheng Lin,Wei Xu
DOI: https://doi.org/10.2147/IJN.S359118
IF: 7.033
2022-09-28
International Journal of Nanomedicine
Abstract:Kai Zhao, 1, 2 Yinzhuo Xie, 2 Xuezheng Lin, 1 Wei Xu 3 1 Taizhou Central Hospital (Taizhou University Hospital), Taizhou University, Taizhou, Zhejiang, 318000, People's Republic of China; 2 Institute of Nanobiomaterials and Immunology, School of Life Science, Taizhou University, Taizhou, Zhejiang, 318000, People's Republic of China; 3 College of Animal Sciences, Zhejiang University, Hangzhou, Zhejiang, 310058, People's Republic of China Correspondence: Kai Zhao, Tel +86 576 88660338, Email Xuezheng Lin, Taizhou Central Hospital (Taizhou University Hospital), Taizhou University, Taizhou, Zhejiang, 318000, People's Republic of China, Email Mucosal tissue constitutes the largest interface between the body and the external environment, regulating the entry of pathogens, particles, and molecules. Mucosal immunization is the most effective way to trigger a protective mucosal immune response. However, the majority of the currently licensed vaccines are recommended to be administered by intramuscular injection, which has obvious shortcomings, such as high production costs, low patient compliance, and lack of mucosal immune response. Strategies for eliciting mucosal and systemic immune responses are being developed, including appropriate vaccine adjuvant, delivery system, and bacterial or viral vectors. Biodegradable mucoadhesive nanoparticles (NPs) are the most promising candidate for vaccine delivery systems due to their inherent immune adjuvant property and the ability to protect the antigen from degradation, sustain the release of loaded antigen, and increase the residence time of antigen at the administration site. The current review outlined the complex structure of mucosa, the mechanism of interaction between NPs and mucosa, factors affecting the mucoadhesion of NPs, and the application of the delivery system based on mucoadhesive NPs in the field of vaccines. Moreover, this review demonstrated that the biodegradable and mucoadhesive NP-based delivery system has the potential for mucosal administration of vaccines. Graphical Keywords: delivery system, nanoparticles, mucosal vaccine, mucosal immunization, mucosal adhesion Graphical Vaccine immunization can prevent and control the spread of infectious diseases by inducing an effective protective immune response, leading to a great improvement in the health of humans and animals. 1 Most pathogenic microorganisms invade the body through the mucosal surface. Therefore, mucosal immunization is one of the most effective strategies against pathogenic microbial infection. 2 However, only very few mucosal vaccines have been developed and approved for clinical use in humans and animals, including intranasally administered live attenuated influenza vaccines FluMist/Fluenz ® and NasovacTM, and orally administered microbiological vaccines. 3 The complexities of mucosal immune regulation and the lack of appropriate antigen delivery systems to access mucosal inductive sites have remained substantial obstacles. 4 A vaccine can work most efficiently if it can elicit both humoral and cellular immune responses. However, conventional vaccines often induce antibody responses with only limited cellular immunity. Many vaccines currently in use are directed toward systemic pathogens or toxins and are administered by intramuscular injection. The intramuscular injection requires using a needle or micro-needle, well-trained medical professionals, and a sterile dosage form, which have apparent shortcomings of high production costs, poor patient compliance (especially children), and lack of mucosal immune response. 5 Therefore, strategies for eliciting the mucosal and systemic immune response are being developed to replace the traditional intramuscular vaccine and improve the immune response of mucosal vaccines, such as appropriate vaccine adjuvant, delivery system, and bacterial or viral vectors. 6,7 Among them, the development of safe and effective mucosal adjuvant and the delivery system remains the focus of mucosal vaccine development. It is well known that mucosa is covered with mucus, which is a viscous gel layer found on various mucosae, such as the eyes, nose, respiratory and gastrointestinal tract, protecting the underlying cells. 8 The mucus layer provides the possibility of mucosal adhesion for delivery systems. Mucoadhesive nanoparticle (NP)-based delivery system has attracted much attention in the field of mucosal vaccines because it can not only protect the loaded antigen from degradation, achieve the optimal sustained release of antigen encapsulated in the NPs, and prolong the antigen delivery time through biological adhesion, but also significantly enhance humoral, c -Abstract Truncated-